Danaher, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from Bank of America Securities reiterated a Buy rating on the stock and has a $230.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ryskin has given his Buy rating due to a combination of factors that highlight Danaher’s strong performance and potential for future growth. The company reported solid second-quarter results, which helped maintain investor confidence. Key drivers such as Bioprocess and Diagnostics met expectations, with Bioprocess revenues showing high single-digit growth and a positive order book trend.
Another reason for the Buy rating is the potential upside in earnings per share (EPS) due to favorable foreign exchange rates and cost-saving measures. Management has indicated an additional 15 to 20 cents of EPS upside not yet included in guidance, providing a buffer against potential challenges. Furthermore, Danaher’s ability to execute in a challenging market environment and the upcoming preliminary FY26 outlook contribute to a reaffirmed long-term bullish view, supporting the Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $225.00 price target.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year.